Absci Corp (ABSI) Stock Analysis

Price updated today · SEC data refreshed 2 months ago ⓘ · Not investment advice

Absci Corp

ABSI Industrials Commercial Physical & Biological Research📄 SEC filings ↗ CUSIP 00091E109
Speculative
Long-term trend (200d) 168% above 200-day Risk 29/100 Moderate
▾ What's in the 29/100 risk score? (higher = riskier)
Fundamental health (43%) 20/100 → +8.6
leverage 20/100 · Altman Z not scored — input unavailable (see Financial Health)
Smart money (short interest + insider buying) (31%) 41/100 → +12.9
Macro backdrop (VIX, curve, credit, fear/greed + week-over-week momentum) (26%) 28/100 → +7.2
Total29/100

Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). It excludes the the Altman Z score, whose retained-earnings input this filer does not report separately, which relies on a proxied (estimated) input. See the Financial Health section for the full balance-sheet read.

💵 Price $9.18 · today 📄 Financials SEC EDGAR · refreshed 2 months ago
📍 START HERE

How to read ABSI (speculative micro-cap)

No model can pin a precise fair value on a company this small — but that does not mean there is nothing to learn. The useful questions are what the price is betting on, and whether the company can survive long enough to deliver it.

Where to start — the sections that matter most for this stock
  1. 1 Reverse-DCF — what growth the price assumes ↓
    The single most useful number here: it backs out the growth the market is paying for. If that figure is "historically unprecedented," the price is running on hype, not fundamentals.
  2. 2 Cash runway ↓
    A pre-profit micro-cap lives or dies on whether it can fund itself to profitability before running out of money and diluting you.
  3. 3 The raw financial statements + the 10-K ↓
    At this scale, the actual numbers, insider ownership, and share-count trend tell you more than any ratio.
Or — what are you trying to decide?
One rule first: never trade out of fear — and that includes the fear of missing out. A stock up 10% a day for three days is excitement, not data. If you can't point to the evidence behind a trade, you're more likely to lose. So whichever of these you are, check the data below before you act.
🚀
"It's surging — should I chase it?"
The momentum / FOMO trade. Before you chase, see whether the people who know it best are quietly selling into the rally.
🏷️
"Is it a cheap bargain?"
The deep-value trade. How far below assets and our value it trades — and whether it's cheap for a reason.
ⓘ No DCF yet — the company isn't generating positive free cash flow

A discounted-cash-flow model can only discount POSITIVE cash flows. ABSI's free cash flow is currently negative — it's reinvesting / still pre-profit — so a forward DCF can't produce a meaningful number. That's a property of the model, not missing data; the full financials and story are below.

What to use instead: This is exactly where the Reverse-DCF earns its keep: it shows the growth the market is ALREADY pricing in, so you can judge whether that's achievable. Pair it with the EV/Sales peer lens, the Rule-of-40 read, and the cash-runway section — the right tools for a pre-profit company.

This note is only about the single DCF fair-value number — ABSI's full financial statements, health scores, and written analysis are all below.

ⓘ Why does ABSI trade at $9.18?

Absci Corp has 136.8 million shares outstanding. At $9.18 per share, the market values all outstanding ABSI equity at $1.3 billion. That's market capitalization, not enterprise value — enterprise value also accounts for debt and cash (ABSI carries little or no debt, so the two are close here). The share price by itself tells you almost nothing — a company can pick any share price by splitting or issuing more shares. What matters is the total value (Market Cap?Market Cap — The total dollar value the market is assigning to the entire company.
Why it matters: This is the number that actually matters when comparing companies. Two companies with the same business but different share counts have the same market cap.
Reference: Mega cap >$200B · Large $10–200B · Mid $2–10B · Small $300M–2B · Micro <$300M
Full explanation →) compared to what the business actually produces. This page values ABSI in Per Share?Per Share — A company-level figure divided by total shares — what one share represents.
Why it matters: Per-share metrics are the only way to fairly compare two companies with different share counts.
Full explanation → economics — what each share represents of the underlying business. Play with the share-price calculator on the homepage →

Loading insider & short-seller data…
🧬 BUSINESS-MODEL ADVISORY — CLINICAL-STAGE BIOTECH

How to read a company this small

This is a clinical-stage biotech with little or no revenue. Standard DCF requires future cash flows to discount — there's nothing to discount yet. The value is entirely in the drug pipeline and the probability that it works.

✅ What actually drives value for this kind of company
  • Drug pipeline — phase of each candidate (Phase I → II → III → FDA approval); each phase has historical success probabilities
  • Total Addressable Market (TAM) of the lead indication — bigger market = bigger payoff if approved
  • Cash runway — months of cash left at current burn rate before they need to raise more (and dilute shareholders)
  • Strategic partnerships — Big Pharma collaborations validate the science and bring milestone payments
  • Patent / exclusivity timeline — how long until generics if approved
  • Insider holdings + management track record — biotech execs with prior wins are a real signal
❌ Metrics that DON'T apply (ignore these even if you see them below)

P/E, P/B, EV/Sales, ROE — meaningless when there's no revenue or earnings. DCF outputs are nonsense.

📚 Where to actually look

ClinicalTrials.gov for trial status. The 10-K's "Pipeline" section. Recent press releases on Phase II/III readouts. Conferences like JPM Healthcare or ASCO.

Classified as Clinical-Stage Biotech (confidence 85%). Disagree? An admin can override via the post edit screen.

PEER BASKET — LIMITED COMPARABLES

⚠ Genuine comparables are scarce at this size, so peer multiples are unreliable here. Treat as rough context only — see 📍 What to focus on above.

How does ABSI stack up against its closest peers?

Ideally we compare ABSI only to same-industry peers, but too few exist in our universe right now, so the basket below mixes in broader-sector names. Treat the multiples as rough context, not a valuation. For a leveraged business, EV/EBIT and FCF yield (both in the table) are usually more reliable than EV/Sales, because revenue multiples ignore differences in margins and debt.

▾ What's "EV / Sales" in plain English?

EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.

EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).

p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.

What peers trade at (p25 / median / p75)
EV / Sales?EV / Sales — For every $1 of yearly revenue, this is how many dollars investors pay to own the whole business (including debt).
Why it matters: Works for pre-profit growth companies where P/E and FCF don't apply. The most apples-to-apples cross-company multiple because it ignores accounting choices.
Reference: 1–3x for mature companies · 4–10x for software/SaaS · 10–20x for hypergrowth · >20x is rare and demanding
Full explanation →		 1.2x / 2.4x / 5.4x
EV / Gross Profit?EV / Gross Profit — Enterprise value divided by gross profit — the multiple paid for what each dollar of sales contributes after direct costs.
Why it matters: More refined than EV/Sales for high-margin businesses (software, marketplaces) where gross margin is the real economic engine.
Reference: 8–15x for SaaS · 15–25x for hypergrowth software · >30x demanding
Full explanation →		 3.0x / 5.9x / 14.0x
EV / EBIT?EV / EBITDA — Enterprise value divided by earnings before interest, tax, depreciation, and amortization.
Why it matters: A classic "what would a private buyer pay" multiple — used in M&A. Strips out tax and capital-structure noise.
Reference: 8–12x for mature businesses · 15–25x for growth · Below 5x often signals distress
Full explanation →		 20.1x / 26.8x / 37.8x

Bold middle number = median peer. Half the peers trade above it, half below. Computed over 8 peers (broad — see caveat); implausible multiples excluded.

What ABSI would be worth at the median peer's multiple
We're not showing a peer-implied price for ABSI: with only 0 genuine same-industry comparables, a median built partly from broader-sector names would be misleading. Lean on the DCF above; use the multiples table only as loose context.

⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.

▾ View peer list (8)
Ticker Company Industry Mcap EV/Sales EV/GP EV/EBIT FCF Yield
XPEL XPEL, Inc. Coating, Engraving & Allie ·fallback $1.3B 2.6x 6.3x 20.1x 4.8%
WLFC WILLIS LEASE FINANCE CORP Machinery, Equipment & Sup ·fallback $1.2B 5.4x — 37.8x 16.7%
VTOL Bristow Group Inc. Air Courier ·fallback $1.2B 1.3x — 12.0x 3.2%
WLDN Willdan Group, Inc. Engineering Services ·fallback $1.4B 2.1x 5.6x 32.2x 4.3%
ULCC Frontier Group Holdings, Inc. Airlines ·fallback $1.4B 0.5x — — 0.2%
TRS TRIMAS CORP Metal Forgings & Stampings ·fallback $1.5B 3.0x 14.0x 47.0x 3.4%
TNC TENNANT CO Refrigeration & Service In ·fallback $1.5B 1.2x 3.0x 21.5x 2.1%
HTZ HERTZ GLOBAL HOLDINGS, INC Auto Rental & Leasing ·fallback $1.7B 7.0x — — 89.8%
FINANCIAL HEALTH SCREENS

Quality & solvency checks

Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.

Altman Z-Score?Altman Z-Score — A bankruptcy-risk score combining 5 financial ratios into one number. Predictive of bankruptcy within 2 years.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
n/a
Not reliably computable

We can't produce a trustworthy Altman Z here: retained earnings weren't separately reported in our data, so a core input would have to be fabricated. Rather than show a categorical "distress" verdict from an invented number, we mark it unavailable. Judge financial health from the leverage, cash position, and the measurable Piotroski checks instead.

Piotroski checks
3 passed · 5 failed · 1 n/a
Partial result, not a standard F-score: 3 of 8 measurable checks passed. 1 of the 9 standard checks couldn't be measured, so this is scored out of 8, not 9 — it isn't comparable to a published F-score.
▾ The checks — what passed, what didn't (and what we couldn't measure)
  • ✗ Positive net income
    Net income -$115.2M in the latest year.
    Why this matters: Does the company actually earn a profit? Sustained losses eventually force it to raise money — diluting you — or take on debt.
  • ✗ Positive operating cash flow
    Operating cash flow -$92.9M (was -$72.4M the prior year).
    Why this matters: Profit can be an accounting figure; cash from running the business is harder to fake. Negative operating cash flow means the core business consumes cash and must be funded externally.
  • ✓ Cash flow backs up reported profit
    Operating cash flow -$92.9M vs net income -$115.2M.
  • ✗ Return on assets improving
    Return on assets -53.3% vs -48.3% a year ago.
    Why this matters: Is the company squeezing more profit out of each dollar of assets than last year? Rising = getting more efficient; falling = the opposite.
  • ✓ Debt load (vs assets)
    Long-term debt is 0.0% of assets vs 1.9% a year ago ($0.0M now).
  • ✓ Short-term liquidity (current ratio)
    Current ratio 6.57x vs 4.67x a year ago.
  • ✗ Share count (dilution)
    Share count rose 24.1% (110.2M → 136.8M year-over-year).
    Why this matters: Issuing lots of new shares splits the pie into more pieces, shrinking your slice. Stable or falling share count protects existing owners.
  • · Pricing power (gross margin) (n/a — data not reported; not scored)
  • ✗ Sales per asset (asset turnover)
    Asset turnover 0.01x vs 0.02x a year ago.
    Why this matters: Asset turnover measures how much revenue each dollar of assets generates. Rising = more productive use of the asset base.

Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.

Cash Runway
3 mo
CRITICAL — under 6 months of cash

Plain English: the company holds about $20M in cash and is burning roughly $93M/year in operations. At that pace, the cash lasts 3 mo before it must raise capital (diluting shareholders), take on debt, or cut spending.

Assumes constant burn and ignores financing/asset sales. For pre-profit biotech and growth companies, this matters more than a DCF — a great drug pipeline is worthless if they run out of money before approval.

INTERACTIVE — TWEAK YOUR ASSUMPTIONS

What if you assume different inputs?

Here's where we land — and what happens if you change the assumptions. Drag the sliders to set your own Discount Rate?Discount Rate — The annual return you demand for taking single-stock risk instead of buying a safe Treasury or index fund.
Why it matters: Higher discount rate = stricter valuation (a stock has to produce more cash to be worth holding). Lower = more generous.
Reference: 8–12% is standard · 9–10% matches S&P 500 historical return · Below 7% is illogical for single-stock risk
Full explanation → (the annual return you demand for single-stock risk) and terminal growth; the value updates live so you can see whether the stock looks cheaper or richer. The discount rate starts at 10.0%, the figure our model used for ABSI. Open Advanced to also change beta, growth and the rate path.

Note: no headline intrinsic value is published for this stock (the valuation is held for a data-quality reason — see the notes above). The calculator below is a what-if tool: the values it produces are your assumptions played out, not our estimate.

4.5% (risk-free)9-10% normal18% (deep-risk)
0%2-3% (GDP)5% (rarely sustainable)

A full intrinsic value isn't shown for ABSI because the valuation is currently held for a data-quality reason (see the guardrail notes above). The reverse-DCF reading still works — it needs only the price and cash flow — but we won't publish a forward value until the underlying data passes our checks.

For comparison — the revenue growth today's price already assumes
—
—

—

⚙ Advanced — tinker with every input (beta, growth, rate path, margin → full intrinsic value)
Where the discount rate comes from — discount rate = risk-free + beta × equity-risk-premium
What you'd earn risk-free from government bonds — the floor under every other rate. Slide it down to model the market expecting rate cuts (value rises); up for higher-for-longer.
The extra yearly return investors demand for owning stocks instead of safe bonds — the price of risk. History runs ~4.5–6.5%; we default to 5.5% (slightly conservative). It's an estimate, not a law — lower it if you think equities are less risky than that.
Inflation quietly eats returns: a 9% gain at 3% inflation is only ~6% in real purchasing power. The intrinsic value above is already in today's dollars (a nominal DCF cancels inflation out of both growth and the discount rate), so this doesn't change the value — it shows what's left of your return after the tax.
Higher beta → higher discount rate (sets the rate above). 1.0 = moves with the market.
What you think ABSI can grow revenue for ~5 years, then fades to terminal.
For a pre-profit company: the % of revenue that eventually becomes free cash flow once mature. (Our published value uses the sector norm.)
All inputs start at the values our model used.

    Copy shareable link to this scenario →

    Price$9.18
    Model IVNot applicable — DCF couldn't price this stock. See Reverse DCF and Football Field below.

    A standard discounted cash flow?DCF — Discounted Cash Flow — sums up all future cash a business will produce, adjusted for the fact that future dollars are worth less than dollars today.
    Why it matters: It is the most fundamentally honest valuation method when applicable — but only works for companies with predictable, positive cash flow.
    Reference: Best for: mature, profitable businesses. Fails for: pre-profit growth, banks, REITs.
    Full explanation →     (DCF) valuation is not meaningful for Absci Corp due to its consistently negative operating cash flow and net income, indicating it is in a cash-burning growth stage. Valuing this company would require detailed projections of its drug pipeline success and future commercialization, which are highly speculative. Investors are likely betting on the potential of its AI-powered drug discovery platform. The primary quantifiable risk is the declining revenue, which has fallen by -8.6% annually over the last four years.

    ⚠️ Revenue declining

    As of 2 months ago

    ANATOMY

    Anatomy of a share

    What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.

    ABSI Absci Corp stock anatomy showing per-share revenue, operating expenses, free cash flow, and debt
    −4,113.7%
    loss
    Where each $1 of revenue goes
    For every $1 of revenue, ABSI currently loses 4,113.7¢ — costs exceed sales. A money-losing business can still be a good investment if losses are shrinking toward profitability; check the trend, not just the snapshot.
    Net margin = net income ÷ revenue (most recent fiscal year).
    Plain English: $9/share buys $0.02 of revenue per share per year, generates $0.84 lost per share per year, and $0.82 of cash burned per share (negative free cash flow). Each share carries $0.00 of debt.
    What's free cash flow / what do these mean?

    Revenue per share — how much the business earns from customers, divided by the number of shares outstanding. Top of the income statement.

    Earnings per share — profit left after operating costs, interest, and taxes, per share. Two versions appear on this page and are not interchangeable: GAAP diluted EPS uses the company's weighted-average diluted share count during the reporting period (this is the "earnings" in "price-to-earnings"); net income per current share divides annual net income by today's share count. They differ whenever the share count has changed.

    Owner-earnings free cash flow per share — the cash the business produces for shareholders. Savng's owner-earnings FCF subtracts capital expenditures and stock-based compensation from operating cash flow (SBC is a real dilution cost even though it's non-cash). This is deliberately more conservative than "standard" FCF, which subtracts only capital expenditures — so our figure is lower than the headline FCF you'll see elsewhere. FCF funds dividends, buybacks, debt repayment, and acquisitions; a company can report positive earnings yet negative FCF.

    Debt per share — total interest-bearing borrowings divided by shares. High debt-per-share next to thin FCF-per-share is a fragility signal.

    THE KEY DEBATE

    What you actually need to decide

    Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.

    🐂 The Bull Case
    For the stock to work, Absci must demonstrate successful advancement of drug candidates through its platform, leading to significant milestone payments or licensing deals, which would reverse the current revenue decline.
    🐻 The Bear Case
    The biggest fundamental risk is the continued negative operating cash flow and declining revenue, which implies a persistent cash burn and potential need for further dilutive equity raises if commercial success is not achieved.
    📌 Signposts to watch — update your view as these print
    • Announcements of new drug discovery partnerships
    • Progress reports on partnered drug candidates entering clinical trials
    • Trends in quarterly revenue growth
    MOMENTUM — WHAT'S GETTING BETTER & WORSE

    The trend, in plain numbers (2024 → 2025)

    Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.

    ✅ Improving

    Nothing clearly improving year-over-year.

    ⚠ Worsening
    • Revenue fell -38% to $2.8M.
    • Free cash flow is negative at -$112.4M — the cash burn widened vs last year.
    • Still unprofitable at -$115.2M — loss widening.
    WHO

    Management & Leadership

    Sean McClain is the founder, Chairman, and CEO of Absci Corp, a position he has held since founding the company in 2011. He leads the company's strategic vision in AI-powered drug discovery.

    Sean McClain
    Chief Executive Officer
    WHAT

    What They Make

    Absci Corp is a biotechnology company that develops an AI-powered integrated drug discovery and development platform to accelerate the creation of new biologics. Its customers are pharmaceutical and biotechnology companies seeking to discover and optimize novel therapeutic proteins.

    End Markets

    Biopharmaceutical R&DDrug DiscoveryTherapeutic Protein Development

    Revenue Drivers

    AI-powered drug discovery services
    Partnerships and collaborations
    Platform licensing
    Market Cap: 1.3BBeta: 2.02
    WHY

    Why Is It Priced Like This?

    Why Customers Pay

    Accelerated drug discovery timelines
    Improved therapeutic protein design
    Reduced R&D costs for partners
    No discounted-cash-flow value for this filer This company's reported free cash flow is negative, so a discounted-cash-flow valuation has no positive cash stream to discount. That is a fact about the business, not missing data — the reported figures below are complete.

    What we use instead: earnings (P/E, EV/EBIT), book value (P/B) — computed from the figures this company does report, shown in the sections below. Those numbers are unaffected by the missing cash-flow data.

    The market is pricing Absci Corp based on the future potential of its AI-powered drug discovery platform, rather than its current financial performance, given its negative net income and operating cash flow. The market may be assigning value to the potential for breakthrough drug discoveries or successful partnerships, which is not in the model. Investors are likely focused on future revenue growth and pipeline advancements, as current revenue is declining at -8.6% per year.

    HOW

    Business Model & Valuation

    How They Make Money

    Research collaboration agreements
    Milestone payments from drug development partnerships
    Potential royalty streams from commercialized drugs

    The company funds itself primarily through equity raises and has no long-term debt, which has fallen from $4M to $0M.

    Growth / Revenue DCF

    Negative free cash flow: revenue/margin growth model used - standard FCF DCF is unreliable for companies still scaling.

    Show advanced inputs
    RevenueGrowth2.0%

    What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.

    WHEN

    Maturity & Competitive Position

    Growth / re-investment phase

    Moat Signals

    Proprietary AI drug discovery platform
    Integrated wet-lab and dry-lab capabilities
    Data-driven protein engineering

    Revenue is declining at -8.6% per year over the last four years.

    WHERE

    Geography & Markets

    Absci Corp is headquartered in the United States, with its operations primarily focused on serving the global biopharmaceutical industry. Exact geographic revenue split is not available from current data sources.

    Geographic Risks

    Reliance on successful partnerships for revenue generation
    High capital requirements for R&D in biotechnology
    SIGNALS

    Market Signals

    These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.

    Model neutral, tape bullish
    RSI?RSI — Relative Strength Index — a 0-100 momentum gauge. Above 70 = overbought; below 30 = oversold.
    Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
    Reference: 30–70 normal · >70 overbought · <30 oversold
    Full explanation →     (14)    73.1OverboughtBought up hard recently — stretched; pullbacks are common from here.
    MACD?MACD — Moving Average Convergence Divergence — compares a fast and a slow price trend to gauge momentum direction.
    Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
    Reference: Line above signal = bullish momentum · below = bearish
    Full explanation →    BullishLine above signalThe fast trend is above the slow trend — short-term momentum is currently upward.
    50-Day Average$4.22Price above (+117.5%)Price above its 50-day average = near-term uptrend.
    200-Day Average$3.42Price aboveThe 200-day line is the long-term trend divider — above it is generally considered a bull market for the stock.
    50 vs 200 CrossGolden50-day above 200-dayA "golden cross" — the medium trend has overtaken the long trend (often read as bullish).

    Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.

    QUALITY

    Data Quality & Risk Flags (6 notes — click to expand/collapse)
    HIGH Revenue declining
    Guardrail Notes (5)
    • FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
    • Terminal growth (3%) capped to 1.6% (80% of near-term growth 2%).
    • INVARIANT: weighted IV is non-positive. Model may not be appropriate.
    • Model implies no positive equity value under these assumptions. Valuation is speculative/low-confidence.
    • Illiquidity discount 7% applied (small/micro-cap — harder to exit, demand a margin).
    FINANCIALS

    Financial Statements (5-year tables — click to expand)

    From Absci Corp's SEC filings (EDGAR).

    Income (5yr)

    YearRevenueNet IncomeEPS
    20252.8M-115.2M$-0.84
    20244.5M-103.1M$-0.94
    20235.7M-110.6M$-1.20
    20224.5M-104.9M$-1.15
    20214.0M-101.0M$-2.08

    Cash Flow (5yr)

    YearOperating CFCapEx− SBC & adj.Free Cash Flow
    2025 -92.9M 1.1M 18.3M -112.4M
    2024 -72.4M 404,000 19.5M -92.3M
    2023 -64.6M 860,000 11.4M -76.9M
    2022 -81.3M 16.2M 12.5M -110.1M
    2021 -60.6M 38.0M 10.6M -109.3M

    How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). Latest year: -92.9M − 1.1M − 18.3M (SBC & adj.) = -112.4M. This is the same owner-earnings FCF definition the valuation model uses, though the DCF's starting value is a projected from revenue × terminal margin, not this single year.

    Balance Sheet

    Total Assets216.3M
    Total Liabilities26.8M
    Equity189.4M
    YOU MIGHT ALSO LIKE

    Similar companies worth a look

    Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.

    PG
    Methodology by Pouyan Golshani, MD — founder of Gighz. Savng was built by a physician for busy professionals: every number on this page comes from SEC filings (EDGAR) and FINRA data through transparent, rules-based models — no analyst opinions, no hidden inputs. How we calculate every number →
    ⚠️ Not investment advice. Automated model outputs, last refreshed May 30, 2026 (the analysis-refresh date, not the latest filing period). All models have blind spots. Full disclaimer →
    ← Browse Stocks See sector peers →
    🔔 Follow $ABSI — free insider alerts
    One email when an insider buys $ABSI on the open market with their own cash — or notably sells outside a scheduled plan. Routine and automated trades filtered out. Follow up to 3 stocks free; Portfolio Watch covers your whole list plus valuation & risk alerts. Double opt-in, unsubscribe anytime.